OBJECTIVE: Remifentanil is a selective μ-opioid agonist with a context-sensitive half-time of
3 to 5 minutes, independent of dose or administration duration. Other desirable effects …

Summary Abstract Remifentanil (Ultiva™), a 4-anilidopiperidine derivative of fentanyl, is an
ultra-short-acting μ-opioid receptor agonist indicated to provide analgesia and sedation in …

Objective: Remifentanil hydrochloride is a new titratable opioid agonist with rapid onset and
offset of action. We present 2 cases of intracranial mass lesions in whom remifentanil was …

Remifentanil is an opioid with a unique pharmacokinetic profile. Its metabolism by
nonspecific esterases results in rapid and uniform clearance leading to highly predictable …

IMPLICATIONS: Remifentanil bolus in severe head trauma patients in the intensive care unit
induces an increase in intracranial pressure related to a decrease in mean arterial blood …

Background and aim: Remifentanil is an ultra‐short‐acting opioid, increasingly used today
in neuroanesthesia and neurointensive care. Its characteristics make remifentanil a …

Current trends toward outpatient surgery have created a demand for shorter acting
anaesthetic agents. Such agents not only provide the anaesthetist with rapid patient …

Background: Remifentanil, an ultra‐short‐acting opioid, is used as an on‐top analgesic in
head trauma patients during transient painful procedures, eg endotracheal suctioning …

Remifentanil (Ultiva™), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-
metabolised, selective μ-opioid receptor agonist, with a pharmacodynamic profile typical of …

Pain is among the worst possible experiences for the critically ill. Therefore, nearly all
intensive care patients receive some kind of pain relief, and opioids are most frequently …